Powerful bactericidal and sterilizing activity of a regimen containing PA-824, moxifloxacin, and pyrazinamide in a murine model of tuberculosis.
PA-824 is a nitroimidazo-oxazine in clinical testing for the treatment of tuberculosis. We report that the novel combination of PA-824, moxifloxacin, and pyrazinamide cured mice more rapidly than the first-line regimen of rifampin, isoniazid, and pyrazinamide. If applicable to humans, regimens containing this combination may radically shorten the treatment of multidrug-resistant tuberculosis.
Nuermberger
Eric
E
Center for Tuberculosis Research, Johns Hopkins University, Baltimore, Maryland, USA. enuermb@jhmi.edu
Tyagi
Sandeep
S
Tasneen
Rokeya
R
Williams
Kathy N
KN
Almeida
Deepak
D
Rosenthal
Ian
I
Grosset
Jacques H
JH
D000818:Animals; D000995:Antitubercular Agents / Q000008:administration & dosage / Q000627:therapeutic use; D001372:Aza Compounds / Q000008:administration & dosage / Q000627:therapeutic use; D015169:Colony Count, Microbial; D004195:Disease Models, Animal; D004359:Drug Therapy, Combination; D005260:Female; D024841:Fluoroquinolones; D006801:Humans; D008168:Lung / Q000382:microbiology; D051379:Mice; D008807:Mice, Inbred BALB C; D000077266:Moxifloxacin; D009169:Mycobacterium tuberculosis / Q000187:drug effects* / Q000302:isolation & purification; D009593:Nitroimidazoles / Q000008:administration & dosage / Q000627:therapeutic use; D011718:Pyrazinamide / Q000008:administration & dosage / Q000627:therapeutic use; D011804:Quinolines / Q000008:administration & dosage / Q000627:therapeutic use; D016896:Treatment Outcome; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy* / Q000382:microbiology
D000995:Antitubercular Agents; D001372:Aza Compounds; D024841:Fluoroquinolones; D009593:Nitroimidazoles; D011804:Quinolines; C410767:pretomanid; D011718:Pyrazinamide; D000077266:Moxifloxacin